{"id":839869,"date":"2025-04-22T07:34:43","date_gmt":"2025-04-22T11:34:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\/"},"modified":"2025-04-22T07:34:43","modified_gmt":"2025-04-22T11:34:43","slug":"briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\/","title":{"rendered":"BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Over 75 patients enrolled in BriaCell\u2019s pivotal Phase 3 study of Bria-IMT<\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>\u2122<\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em> plus immune check point inhibitor in metastatic breast cancer (MBC)<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>54 clinical sites across 15 states currently enrolling patients including Sylvester Comprehensive Cancer Center, Cancer Care Northwest, Hematology Oncology Associates of Fredericksburg, Northwestern University, Manhattan Hematology\/Oncology Associates, New York Cancer and Bood Specialists, and Texas Oncology-Baylor Charles A. Sammons Cancer Center<\/em><br \/>\n          <\/strong>\n        <\/li>\n<\/ul>\n<p align=\"justify\">PHILADELPHIA and VANCOUVER, British Columbia, April  22, 2025  (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that its ongoing pivotal Phase 3 clinical study (listed on ClinicalTrials.gov as <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=01WXp7Na0MXUsTvbcnP1VACc5wp_hJMGJ5Gf54MJ5bZEEBG8ftZUeXus5phimbRCqzxK7opUhFqQ7zsHWN0qe29LGBxnnHirGVkwtFWXEYxsYXfimgFkXS4MsBdlD59G\" rel=\"nofollow\" target=\"_blank\">NCT06072612<\/a>) has consented over 100 and has enrolled over 75 patients. BriaCell anticipates completing patient enrollment in late 2025 or early 2026, and may report top line data as early as H1-2026.<\/p>\n<p align=\"justify\">BriaCell\u2019s pivotal Phase 3 clinical study is evaluating BriaCell\u2019s lead clinical candidate, Bria-IMT, plus immune check point inhibitor versus physician\u2019s choice in <u>a<\/u>dvanced metastatic <u>b<\/u>reast <u>c<\/u>ancer (Bria-ABC).<\/p>\n<p align=\"justify\">\u201cWe are pleased at the expanding patient enrollment in our Phase 3 study, and expect this to continue to grow,\u201d stated Dr. William V. Williams, BriaCell\u2019s President &amp; CEO. \u201cWe believe our novel therapeutic approach has the potential to transform cancer care for metastatic breast cancer patients, and are determined to bring our novel immunotherapy to market to help these patients.\u201d<\/p>\n<p align=\"justify\">\u201cEnrollment pace and clinical investigator interest in our Bria-ABC study is above any I have seen,\u201d noted Giuseppe Del Priore, MD, MPH, BriaCell\u2019s Chief Medical Officer. \u201cWe would like to thank our dedicated clinical investigators and patients for participating in this important study. Through their efforts, we will advance our novel cancer immunotherapy to other MBC patients whose medical needs remain unmet.\u201d<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <u>About BriaCell\u2019s Pivotal Phase 3 Clinical Study of Bria-IMT Combination Regimen in MBC patients<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">Fifty-four clinical sites in the US are actively enrolling patients in BriaCell\u2019s pivotal Phase 3 study in metastatic breast cancer. Additional sites are in various stages of start-up.<\/p>\n<p align=\"justify\">Interim data will be analyzed once 144 patient events (deaths) occur, comparing the overall survival (OS) in patients treated with the Bria-IMT combination regimen versus those treated with physician\u2019s choice as the primary endpoint. Positive results of the pivotal Phase 3 study could result in full approval and marketing authorization for Bria-IMT in MBC patients. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=c7lCIUvXW6Vsq_bHwxhKNVXx0X6uEIMhjQZbJrPWd5Zlk-zx0hPcJNHZRRgouYvsGEZfo3wvO6bgvNNj-KSatkbJfEm9wTtknniFE5zWovrC92qW39sNwkkJO8E7zdARBt-WCO4HLF1tHTcenAQw4oyYV3cR9vD7rNH21vdjMefD9OEL5cN-tHCbLsT5FfXUeAeUpCrgtolV4ZIg89Kzb18SWV9nzH9uIUVEYMx--vBm-9JQl8asHAg-0BuFFuTY7bUoiuNGM5xqauy474tXMF1dvpk2pe75oFuBywZ8k7R1pBWMb5WRlNIsWe5wEdTqx7OqW_q0q8c9Iu4Na_ZDIg==\" rel=\"nofollow\" target=\"_blank\">BriaCell recently announced positive Phase 2 survival data in a similar MBC patient population treated with the same Bria-IMT combination regimen<\/a>. The Bria-IMT combination regimen has received FDA Fast Track designation.<\/p>\n<p align=\"justify\">For additional information on BriaCell\u2019s pivotal Phase 3 study of Bria-IMT and an immune check point inhibitor in metastatic breast cancer, please visit ClinicalTrials.gov <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=01WXp7Na0MXUsTvbcnP1VMtMyTpZZFdF7fFyLc6AJcf3jVL5kyemQQpQoBJTuOwZadPwRA9ylOgu72AufzeZ88xAn9WZYcMTl14Ra29sBQoWAvr-FfS6vDRvzkp3Mgr_\" rel=\"nofollow\" target=\"_blank\">NCT06072612<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About BriaCell Therapeutics Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UoTjcvBuucdac4-YTgogNqF8JXdNNxYPxoUhPuzmxaTwKzvjG4FYcobgdDguiCpALHSmuTZ-iVT_79geG-8wJpJSesj4DGmpk6_fYpTbkJQ=\" rel=\"nofollow\" target=\"_blank\">https:\/\/briacell.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about the Company\u2019s anticipated expansion of patient enrollment, timeline for completing patient enrollment and timeline for reporting top line data in its ongoing pivotal Phase 3 clinical study; the Company\u2019s beliefs regarding its ability to bring their novel immunotherapy to the market; the Company\u2019s beliefs regarding the Bria-IMT combination regimen\u2019s potential to transform cancer care for metastatic breast cancer patients; the Company offering its novel cancer immunotherapy to other metastatic breast cancer patients; the Company\u2019s plans and timelines regarding its analysis of interim data on the Bria-IMT combination regimen, and how such data will be analyzed; and the Company\u2019s beliefs regarding Bria-IMT receiving full approval and marketing authorization for metastatic breast cancer patients, are based on BriaCell\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements, such as those are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading \u201cRisks and Uncertainties\u201d in the Company\u2019s most recent Management\u2019s Discussion and Analysis, under the heading \u201cRisk Factors\u201d in the Company\u2019s most recent Annual Information Form, and under \u201cRisks and Uncertainties\u201d in the Company\u2019s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company&#8217;s profiles on SEDAR+ at <strong><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Y0ZgjRunG7c5NJoUD3vSu4a6xVXtTtVWXcqY5PcDfhq3gVSQ5x9F93axE6UdJ1lGycQrpkHwnhcOJaoPmNs2PzA5Nu4iJjuFI-YqUer816E=\" rel=\"nofollow\" target=\"_blank\">www.sedarplus.ca<\/a><\/u><\/strong>\u00a0and on EDGAR at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Y0ZgjRunG7c5NJoUD3vSu-AmMeVXopwIqFltMORBJOicyT5EJv9POEG-Qa9EsJ4eOQTEldimFEgmzvtJAA2huw==\" rel=\"nofollow\" target=\"_blank\"><strong>www.sec.gov<\/strong><\/a>. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n<p align=\"left\">\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>William V. Williams, MD<br \/>President &amp; CEO<br \/>1-888-485-6340<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-XElnuT7zdtSdBlhl9-Vu2r6kkg1TPpFgVnipbNCpcxIRXQfWH-62qoQIrDIRqknoYXUuY6Ml3IsI4b43hjF9RoymKyUk2aS4rkJsyEKar8=\" rel=\"nofollow\" target=\"_blank\">info@briacell.com<\/a>\u00a0<\/p>\n<p align=\"left\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FcyXRdmvaT4JoNRvvVtm7jaMDZhsRfopKNdx6PLi1tO7i_e35PY863Qsd3vGt4A7SsAKd3jBhpETD88_sMFEmK4gnAhiYx1hl84hz6Eyirg=\" rel=\"nofollow\" target=\"_blank\">investors@briacell.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNjE5MyM2ODk3MzQ0IzIwOTA2NTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjU1ZWM5ZWUtZjgyMy00MjQyLWFmYTQtYzBiMDA1YzNiM2YyLTExMDIyMjktMjAyNS0wNC0yMi1lbg==\/tiny\/BriaCell-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Over 75 patients enrolled in BriaCell\u2019s pivotal Phase 3 study of Bria-IMT \u2122 plus immune check point inhibitor in metastatic breast cancer (MBC) 54 clinical sites across 15 states currently enrolling patients including Sylvester Comprehensive Cancer Center, Cancer Care Northwest, Hematology Oncology Associates of Fredericksburg, Northwestern University, Manhattan Hematology\/Oncology Associates, New York Cancer and Bood Specialists, and Texas Oncology-Baylor Charles A. Sammons Cancer Center PHILADELPHIA and VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that its ongoing pivotal Phase 3 clinical study (listed on ClinicalTrials.gov as NCT06072612) has consented over 100 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-839869","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Over 75 patients enrolled in BriaCell\u2019s pivotal Phase 3 study of Bria-IMT \u2122 plus immune check point inhibitor in metastatic breast cancer (MBC) 54 clinical sites across 15 states currently enrolling patients including Sylvester Comprehensive Cancer Center, Cancer Care Northwest, Hematology Oncology Associates of Fredericksburg, Northwestern University, Manhattan Hematology\/Oncology Associates, New York Cancer and Bood Specialists, and Texas Oncology-Baylor Charles A. Sammons Cancer Center PHILADELPHIA and VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that its ongoing pivotal Phase 3 clinical study (listed on ClinicalTrials.gov as NCT06072612) has consented over 100 &hellip; Continue reading &quot;BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-22T11:34:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNjE5MyM2ODk3MzQ0IzIwOTA2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)\",\"datePublished\":\"2025-04-22T11:34:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\\\/\"},\"wordCount\":907,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzNjE5MyM2ODk3MzQ0IzIwOTA2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\\\/\",\"name\":\"BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzNjE5MyM2ODk3MzQ0IzIwOTA2NTg=\",\"datePublished\":\"2025-04-22T11:34:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzNjE5MyM2ODk3MzQ0IzIwOTA2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzNjE5MyM2ODk3MzQ0IzIwOTA2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\/","og_locale":"en_US","og_type":"article","og_title":"BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC) - Market Newsdesk","og_description":"Over 75 patients enrolled in BriaCell\u2019s pivotal Phase 3 study of Bria-IMT \u2122 plus immune check point inhibitor in metastatic breast cancer (MBC) 54 clinical sites across 15 states currently enrolling patients including Sylvester Comprehensive Cancer Center, Cancer Care Northwest, Hematology Oncology Associates of Fredericksburg, Northwestern University, Manhattan Hematology\/Oncology Associates, New York Cancer and Bood Specialists, and Texas Oncology-Baylor Charles A. Sammons Cancer Center PHILADELPHIA and VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that its ongoing pivotal Phase 3 clinical study (listed on ClinicalTrials.gov as NCT06072612) has consented over 100 &hellip; Continue reading \"BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-22T11:34:43+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNjE5MyM2ODk3MzQ0IzIwOTA2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)","datePublished":"2025-04-22T11:34:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\/"},"wordCount":907,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNjE5MyM2ODk3MzQ0IzIwOTA2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\/","name":"BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNjE5MyM2ODk3MzQ0IzIwOTA2NTg=","datePublished":"2025-04-22T11:34:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNjE5MyM2ODk3MzQ0IzIwOTA2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNjE5MyM2ODk3MzQ0IzIwOTA2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/839869","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=839869"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/839869\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=839869"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=839869"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=839869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}